Aligos Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Corporate Dr Fl 2, South San Francisco...Phone Number
(800) 466-6059Website
www.aligos.comRevenue
<$5 MillionStock Symbol
ALGSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.Explore more
Aligos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aligos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aligos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Aligos Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Aligos Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Aligos Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Aligos Therapeutics
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Aligos Therapeutics launches new products
Earning: See what the market has to say on Aligos Therapeutics recently announced quarterly report
Check if Aligos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Aligos Therapeutics
Find 2 more new buyers
Compare Similar Companies to Aligos Therapeutics
Compare insights from companies similar to Aligos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aligos Therapeutics
<$5M
51-200
Public
$458.6M
2018
SC
Sushmita ChandaExecutive Vice President & Chief Development Officer
Company Profile Activity
Activity Insights
Aligos Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aligos Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aligos Therapeutics.
Aligos Therapeutics financials insights
Gather financial insights about Aligos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$100M
2020
Series B
$125M
Stock Offering
$150M
2021
Stock Offering
$83.6M
Aligos Therapeutics Tech Stack
A closer look at the technologies used by Aligos Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Corporate Strategy, Finance, Mergers
Person-Based
Medical Research
Person-Based
Events, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Earnings, Finance, Investor Relations
Aligos Therapeutics News & Media
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Breakthrough Therapy Designation granted for pevifoscorvir sodium in ChinaAligos Therapeutics Presents Positive Data at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain.Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on theAligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s first quarter 2026 financial results on Thursday, May 7, 2026, after the close of the U.S. financial markets.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Aligos Therapeutics
Sign Up For FreeTo access detailed company insights
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise i... Read More
